KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Amgen (AMGN) over the last 13 years, with Q3 2025 value amounting to $127.0 million.

  • Amgen's Share-based Compensation fell 661.76% to $127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.0 million, marking a year-over-year decrease of 969.48%. This contributed to the annual value of $530.0 million for FY2024, which is 2296.98% up from last year.
  • Latest data reveals that Amgen reported Share-based Compensation of $127.0 million as of Q3 2025, which was down 661.76% from $157.0 million recorded in Q2 2025.
  • Amgen's Share-based Compensation's 5-year high stood at $161.0 million during Q4 2023, with a 5-year trough of $47.0 million in Q1 2023.
  • For the 3-year period, Amgen's Share-based Compensation averaged around $120.9 million, with its median value being $127.0 million (2025).
  • In the last 5 years, Amgen's Share-based Compensation skyrocketed by 11914.89% in 2024 and then plummeted by 1747.57% in 2025.
  • Quarter analysis of 3 years shows Amgen's Share-based Compensation stood at $161.0 million in 2023, then fell by 16.77% to $134.0 million in 2024, then fell by 5.22% to $127.0 million in 2025.
  • Its last three reported values are $127.0 million in Q3 2025, $157.0 million for Q2 2025, and $85.0 million during Q1 2025.